Business model incorporates researching the genome mapping of the 4 types of leukemia, execute modification of Natural Killer Leukocytes, further lab testing until ready for phase 1 trials, and request for FDA Office of Orphan Product Development Grant for phase 1 clinical trial. After phase 1 is complete, we will use Right to Try Law to accelerate phase 2 clinical trials. Finish Phase 3 trials, begin developing cure, and distribute cure.